Summary
Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the second quarter ended June 30, 2022, on July 28, 2022. This 8-K filing primarily serves to furnish the press release containing these results. While the specific financial figures are not detailed within the 8-K itself, the press release, incorporated by reference, would contain key performance indicators such as revenue, net income/loss, and earnings per share. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial performance and any forward-looking statements made by the company. This filing does not introduce any new material events beyond the earnings announcement. As is standard for earnings releases furnished under Item 2.02, the information is not deemed "filed" for purposes of certain securities laws, meaning it does not carry the same liabilities as formally filed documents unless specifically incorporated into other filings. Investors should use this information as a starting point and delve into the press release for a comprehensive understanding of Alnylam's recent financial standing and operational updates.
Key Highlights
- 1Alnylam Pharmaceuticals (ALNY) reported its Q2 2022 financial results on July 28, 2022.
- 2The 8-K filing primarily serves to furnish the press release containing the Q2 earnings.
- 3Investors must consult Exhibit 99.1 (the press release) for detailed financial performance data.
- 4No new material events beyond the earnings announcement are detailed in this 8-K.
- 5Information furnished under Item 2.02 is not considered 'filed' for certain legal purposes.
- 6The filing includes the Cover Page Interactive Data File (XBRL).